Peripheral blood samples and PBMCs collected from pediatric CHD patients before and after CPB were subjected to ex vivo stimulation with PBS as the control, the NOD1 agonist Tri-DAP, and the NOD2 agonist MDP to assess the inflammatory cytokine response. This evidence concerns the gene NOD2 and coronary artery disorder.